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Introduction
Hypertension is a risk factor for cardiovascular disease (CVD), the
leading cause of death in the United States. The treatment and control of hypertension is inadequate, especially among patients
without health insurance coverage. The Affordable Care Act
offered an opportunity to improve hypertension management by
increasing the number of people covered by insurance. This study
predicts the long-term effects of improved hypertension treatment
rates due to insurance expansions on the prevalence and mortality
rates of CVD of nonelderly Americans with hypertension.

Methods
We developed a state-transition model to simulate the lifetime
health events of the population aged 25 to 64 years. We modeled
the effects of insurance coverage expansions on the basis of published findings on the relationship between insurance coverage,
use of antihypertensive medications, and CVD-related events and
deaths.

Results
The model projected that currently anticipated health insurance expansions would lead to a 5.1% increase in treatment rate among
hypertensive patients. Such an increase in treatment rate is estimated to lead to 111,000 fewer new coronary heart disease events,
63,000 fewer stroke events, and 95,000 fewer CVD-related deaths
by 2050. The estimated benefits were slightly greater for men than
for women and were greater among nonwhite populations.

Federal and state efforts to expand insurance coverage among
nonelderly adults could yield significant health benefits in terms of
CVD prevalence and mortality rates and narrow the racial/ethnic
disparities in health outcomes for patients with hypertension.

In the United States, approximately 78 million people — or 1 in 3
adults — have hypertension, defined as systolic blood pressure of
140 mm Hg or higher or diastolic blood pressure of 90 mm Hg or
higher (1). Hypertension is a risk factor for cardiovascular disease
(CVD), contributing to 35% of myocardial infarctions (MIs) and
strokes, and 49% of heart failures (2). It is estimated that a 5 mm
Hg reduction of systolic blood pressure in the population would
lead to a 9% to 14% reduction in CVD-related mortality rates (3).
Thus, prevention of elevated blood pressure can avert many CVDrelated deaths.
Despite the low cost of antihypertensive medications, there is inadequate management of blood pressure at the population level.
National surveys conducted during 2011–2012 show that only
72% of people with hypertension were taking antihypertensive
drugs, and 53% of hypertensive patients had their blood pressure
under control (4). Lack of insurance coverage is a critical barrier
to better treatment of hypertension. Compared with insured people
with hypertension, uninsured people with hypertension are 4.4
times more likely to have an unmet need for medical care and prescription drugs (5) and have lower treatment and control rates (6).
Health insurance expansions under the Affordable Care Act
(ACA) offered an opportunity to improve hypertension management by increasing the number of people receiving clinical preventive services (such as routine blood pressure checks) without
cost sharing and by lowering patients’ out-of-pocket costs of antihypertensive medications. The Congressional Budget Office estimated that by 2024, Medicaid expansions and federal subsidies
to buy insurance in the Health Insurance Marketplaces would help
25 million uninsured people get insurance coverage (7). However,
little research has been done to understand the extent to which
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such expansion in coverage is likely to improve the health status
of hypertensive patients in the long term. We aimed to project the
long-term effects of health insurance expansions on hypertension
treatment, CVD incidence rates, and disease-related mortality
rates, using a state-transition (Markov process) model that simulates the lifetime health events among cohorts of the nonelderly
hypertensive population.

Methods
On the basis of empirical evidence that people with health insurance are more likely to receive antihypertensive medications and
other medical interventions than those who are uninsured (8), we
hypothesized that health insurance expansions would lead to fewer CVD events and related deaths among the hypertensive population. The goal of our model was to estimate changes in the incidence of stroke, coronary heart disease (CHD) — including MI and
angina pectoris — and disease-caused mortality rates for a cohort
of nonelderly adults, given the expected changes in health insurance rates and first-dollar coverage of preventive services among
adults following implementation of the ACA. The simulation
model ran separately for 8 discrete cohorts stratified by sex and
age (in 10-year increments from 25 to 64). Previous research has
used comparable approaches to project expected effects on CVD
outcomes from changes in blood pressure or cholesterol levels as a
result of prevention and treatment (9–11). However, given the
well-established evidence that antihypertensive medications are
highly effective in preventing CVD, we explicitly modeled health
effects through improvement in the medication rate in the population.
Our simulation model estimated how changes in one input (ie,
health insurance rate) lead to changes in other outputs (eg, incidence of CVD events) while isolating the effects of other confounding factors. Findings from this study can contribute to the understanding about the long-term impact of access to health insurance
on the hypertensive population. The model also helps to assess
changes in population health outcomes over time, complementing
existing evidence from short-term retrospective data.

event is associated with a certain probability of death, depending
on the disease type and the patient’s age, insurance status, and disease history. Insurance status was randomly assigned at the beginning of each year, and the probability of insurance varied according to 3 policy scenarios.
Figure 1 shows the state transitions for one piece of the model,
where individuals start the year with a history of MI. At the end of
each iteration, the model removes simulated deaths from each
age–sex cohort, and the remaining lives carry on to the next simulated year. The lives that carry over also retain the history of cardiovascular outcomes acquired in the year that just completed,
which changes the risk profile of the cohort (ie, the distribution of
the 4 CVD risk groups) for the following year. This iterative process continues for the equivalent of 37 simulated years
(2014–2050). Following the conclusion of the iterative model runs
of each age–sex cohort, we computed the accumulated number of
new CVD events and deaths until 2050. Finally, we computed the
population-level CVD incidence and deaths by aggregating outcomes of all cohorts according to the age–sex distribution of hypertension prevalence (4).

Figure 1. Simplified diagram of the Markov process. Abbreviation: CHD,
coronary heart disease; CVD, cardiovascular disease; MI, myocardial
infarction.

Model design
Beginning with simulated year 2014 and at the start of each iteration (a calendar year), the model separates individuals in each cohort into 4 separate states: history of MI, history of angina, history of stroke, or “well” (ie, hypertension with no CVD history).
In each simulated year, every individual may develop a CHD or
stroke event, stay CVD-free, or die of a non-CVD cause; the probabilities of these events vary depending on whether an individual
receives antihypertensive medications. Furthermore, each CVD

Policy scenarios and data input measures
We compared the population-level incidence of CVD and deaths
by 2050 under 3 policy scenarios:
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1. The baseline scenario simulated the absence of reforms included in the ACA, with percentages insured and uninsured remaining roughly the same as they were before enactment (12).
2. The first expansion scenario simulated an expansion based on
current expectations (as of January 2014) for insurance expansions under the ACA and assumed that all undecided states
will opt out of expanding Medicaid throughout 2050. Insurance coverage levels were based on research results reported
by Nardin et al (13), which estimated that 13.9 million previously uninsured nonelderly adults would gain health insurance
coverage under the ACA. These estimates were consistent with
the observed decrease in the number of uninsured adults
between 2013 and 2015 (14).
3. The second expansion scenario simulated an expansion that
achieves 100% insurance for all age groups. This scenario goes
beyond full implementation of the ACA, estimating the upper
bounds on insurance-related effects that help to put the results
from other scenarios into context.
The average annual incidence of CHD and stroke, by age and sex,
was computed using β coefficients from Framingham CVD risk
functions (15). The predictions of these functions have been validated with data from other ethnically diverse studies (16) and have
been widely used in simulation models of CVD prevention
strategies (10,17). Risk factors for CHD and stroke were derived
from National Health and Nutrition Examination Survey
2011–2012 data, including sex, age, systolic blood pressure,
smoking status, level of total serum cholesterol, level of highdensity lipoprotein cholesterol, and the presence of diabetes. The
distribution of CHD events (MI, stable angina, and unstable
angina) was obtained from the Healthcare Cost and Utilization
Project hospital inpatient data (18).
The likelihood of receiving antihypertensive medications by insurance status was based on estimates reported by Brooks et al (19)
The age-specific effects of antihypertensive medications on CHD
and stroke and 1-year mortality rates after CVD events were collected from published medical literature (12,13,20–30). (For complete information on input parameters, see the Appendix.)
We estimated the effects of health insurance expansions by race/
ethnicity using the same process. Framingham CVD risk functions were used to estimate the probabilities of CVD events separately for each age-racial/ethnic group. For these scenarios, estimates of pre-ACA and post-ACA insurance rates by race/ethnicity
were based on estimates reported by Clemans-Cope et al (31).

Sensitivity analysis
We used Monte Carlo simulations to account for uncertainties
about the disease transition probabilities at the individual level that
could affect future outcomes. The probability of each CVD event
was defined as a normally distributed random variable with means
and standard deviations estimated from the Framingham CVD risk
functions. The standard errors of disease prevalence and mortality
rates were obtained from results of 1,000 simulations.
Past research found that longer periods without insurance are associated with access problems; thus, greater health benefits are likely
to accrue for individuals with continuous coverage throughout
their lifetimes (32). To test the effects of continuous coverage, we
estimated an alternative model in which individuals in the same
sex-age-insurance cohort remain either insured or uninsured for
the duration of the simulation (Appendix). Additional analyses investigated the effects of including people with prehypertension
(defined as systolic blood pressure of 120–139 mm Hg or diastolic blood pressure of 80–89 mm Hg). All analyses were performed
using Treeage Pro 2013 (Treeage Software, Williamstown, Massachusetts).

Results
Under the first expansion scenario, where all states currently undecided about Medicaid expansion opt out, the proportion of the current cohort of hypertensive patients being treated with antihypertensive medications is estimated to increase from 56.7% to 59.5%
(Table 1). Younger adults would experience proportionally greater increase in treatment rates: rates for people aged 25 to 34 would
increase by 9.4%, and rates for people aged 55 to 64 would increase by 3.4%. The changes in projected treatment rates were larger for men than for women, primarily because the current treatment rates for men are significantly below those for women. If all
adults aged 25 to 64 obtained insurance coverage, the hypertension treatment rate would rise to 63.5%.
The model predicted that if currently undecided states opt out of
the Medicaid expansion and hypertension treatment rates remain
constant, by 2050, the number of new cases of CHD would be reduced by 111,000 (0.55%) and the number of new cases of stroke
by 63,000 (0.75%); the number of CVD-related deaths would decline by 95,000 (1.16%) (Table 2). If all currently uninsured
people get insurance coverage, the incidence of CHD and stroke
would decline by 1.48% and 1.3% respectively, and CVD-related
mortality would decline by 2.73%. Both sexes were expected to
benefit from the insurance expansions; the estimated benefits are
greater for men than for women. Although the absolute numbers
of new cases and deaths averted were estimated to be greater for
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the white population, the relative improvement in outcomes was
expected to be greater for nonwhite Hispanics (Table 3). Relative
to the baseline scenario, Hispanics were expected to have 2.07%
fewer CHD cases and 1.06% fewer stroke cases under the first expansion scenario, compared with the 0.51% and 0.5% reductions
for whites. The health effects of averted CVD events therefore
translate into a greater mortality rate reduction for Hispanics than
whites (3.84% vs 1.19%).
All age groups were expected to have reduced incidence of CVD
events and lower mortality rates from CVD following the insurance expansions (Figure 2). The estimated reductions in mortality
were largest for adults aged 25 to 34: by 1.2% to 3.2% if currently
undecided states opt out of Medicaid expansions, and by 2.4% to
9.4% if all adults eventually have insurance coverage. Again, the
estimated benefits are greater for nonwhite populations in each age
group.

Figure 2. Estimated reduction in cardiovascular events and mortality rates
under insurance expansions for white, black, and nonwhite Hispanic
populations, by age group. These charts illustrate the racial/ethnic-specific
effects of insurance coverage expansion by age group. Outcomes are
measured by percentage reduction in cardiovascular events and mortality
rates. Scenario 1 assumes currently undecided states opting out of Medicaid
expansion, and scenario 2 assumes the entire US population is covered by
insurance.

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.

4

Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2015/15_0111.htm

PREVENTING CHRONIC DISEASE

VOLUME 12, E105

PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY

JULY 2015

As expected, the model predicted greater health effects when individuals were assumed to maintain their insurance status over time
(Appendix). In the first expansion scenario, improved medication
rates would prevent 307,000 CHD cases (1.42%), 138,000 stroke
cases (1.18%), and 217,000 CVD-related deaths (2.61%). In the
second scenario, there would be 485,000 fewer CHD cases
(2.24%), 266,000 fewer stroke cases (2.26%), and 513,000 fewer
CVD-related deaths (6.15%).
When including all adults with prehypertension, the estimated relative effects of expansion remain similar to the baseline results
(Appendix). Nevertheless, the predicted population-wide benefits
in terms of the CVD cases averted and lives saved are greater, because an additional 53 million adults with prehypertension would
benefit from early interventions due to coverage expansions. Specifically, the model projects that insurance expansions would reduce CHD cases by 253,000 to 535,000; stroke cases by 77,000 to
189,000; and deaths by 165,000 to 364,000.

Discussion
One objective of the ACA is to improve disease prevention by expanding health insurance coverage and access to preventive care.
Findings from this study indicate the potential public health benefits from such efforts. It is estimated that improved hypertension
treatment rates due to insurance expansions would prevent
174,000 to 408,000 new CHD and stroke cases by 2050, a 0.61%
to 1.43% decline from the baseline. Heidenreich et al (33) estimated that CHD and stroke cost $197.3 billion (2008 dollars) in
2015, including direct medical costs and indirect costs from illness and premature death. Applying these estimates to our results
yields a cost savings of $1.2 to $2.8 billion per year. We also projected that increased hypertension treatment rates due to expansion would prevent 95,000 to 222,000 CVD-related deaths among
the current cohort of nonelderly hypertensive patients, representing 2,568 to 6,000 lives saved annually.
These results build on findings from the lottery-based Medicaid
expansion in Oregon, which indicated that previously uninsured
low-income adults who were randomly selected into Medicaid reported increased use of medication for hypertension, hypercholesterolemia, and diabetes, and better self-reported physical and mental health, than low-income adults who remained uninsured (34).

Nevertheless, significant improvement in clinical outcomes, such
as blood pressure, cholesterol level, and glucose level, was not observed in the first 2 years following the expansion. As the authors
acknowledged, the short study period may be a limiting factor, because the health benefits of having insurance may not be realized
immediately. Thus, our results indicate that when considering
whether to implement health insurance expansions, states should
consider the population health benefits and cost-savings that
would be realized in the long term.
Our estimate of a 1.2% to 2.7% reduction in population mortality
is smaller than the estimate by Sommers et al of 6% (35). There
are several explanations for this difference. Besides coverage for
antihypertensive drugs, health insurance provides patients with
timely outpatient care, chronic disease management, and laboratory services, all of which are likely to generate health benefits that
are not captured in our model. Our estimates also exclude the
health effects of insurance expansion on other conditions such as
diabetes and mental illness. Given that the insurance coverage provision under the ACA is expected to cost $76 to $145 billion annually for the next decade (7), more research is needed to comprehensively evaluate the health and economic effects of this health
system reform.
Our study has limitations. Our model predicted greater benefits for
certain subpopulations. Men would receive greater benefits than
women (eg, 1.23% decrease in mortality for men vs 1.07% for women in the first expansion scenario), because men have a higher
lifetime risk of CVD (36). Young and middle-aged adults (25 to
54 y) would experience proportionally greater reductions in mortality rates, largely because early treatment of hypertension effectively prevents or delays the onset of CVD.
Our findings also suggest that the ACA’s insurance expansions
would narrow the racial/ethnic disparities in health outcomes, a
finding consistent with recent studies (35,37). In particular, nonwhite Hispanics would proportionally benefit the most from the
coverage expansions because they have the lowest pre-ACA insurance rate among all racial/ethnic groups (31). Blacks would also
receive proportionally larger benefits than whites, because they
have the highest rates of hypertension as well as other CVD risk
factors, such as diabetes and obesity (38).
There are several limitations of this analysis. As with almost all
policy assessment tools, the size of our estimates depends on a
range of assumptions about the population in future decades. As
discussed previously, our analysis focuses on the impact of improved medication rates and does not fully consider other potential benefits from insurance expansions. Our main analysis also
does not account for possible effects of health insurance expan-
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sions on preventing the onset of hypertension among healthy
adults and adolescents — for example, potential reduction in hypertension prevalence because of lifestyle interventions and health
education. As shown in the sensitivity analysis, insurance expansions also have positive effects on people with prehypertension.
Conversely, factors that delay enrollment of uninsured individuals
in Medicaid, insurance exchanges, or both, or that limit their ability to access care once insured, may lower the estimated effects.
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Even with these limitations, this study demonstrates that improved hypertension treatment through the expansion of health insurance coverage would yield substantial health benefits for the 55
million nonelderly hypertensive adults in the United States. Future research should include additional analyses of the effects of
comprehensive insurance benefit packages and improved blood
pressure monitoring in home and ambulatory settings.
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Tables
Table 1. Estimated Effects of Health Insurance Expansion on Hypertension Treatment Rates by 2016
Nonelderly Adults With Hypertension, % Receiving Treatment (% Change Under Expansion)
Scenario/
Sex

All adults (N =
54,697,510)

Aged 25–34 (n =
3,911,740)

Aged 35–44 (n =
10,190,086)

Aged 45–54 (n =
17,326,094)

Aged 55–64 (n =
23,269,590)

Baseline scenario: no expansion
US total

56.7 ( — )

51.5 ( — )

53.3 ( — )

57.0 ( — )

58.8 ( — )

Male

50.8 ( — )

45.9 ( — )

47.2 ( — )

51.6 ( — )

53.0 ( — )

Female

62.5 ( — )

58.8 ( — )

59.8 ( — )

62.8 ( — )

63.8 ( — )

Scenario 1: currently undecided states opting out of Medicaid expansion
US total

59.5 (5.1)

56.3 (9.4)

56.9 (6.8)

60.2 (5.6)

60.7 (3.4)

Male

54.3 (6.8)

51.4 (12.1)

51.4 (8.9)

55.4 (7.2)

55.4 (4.5)

Female

64.8 (3.7)

62.7 (6.6)

62.7 (4.9)

65.4 (4.2)

65.4 (2.6)

Scenario 2: all US population under insurance coverage
US total

63.5 (12.1)

62.9 (22.2)

63.3 (18.9)

63.4 (11.1)

63.8 (8.6)

Male

59.0 (16.1)

59.0 (28.6)

59.0 (25.0)

59.0 (14.3)

59.0 (11.4)

68.0 (8.8)

68.0 (15.6)

68.0 (13.8)

68.0 (8.2)

68.0 (6.6)

Female
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Table 2. Estimated Effects of Health Insurance Expansion on Nonelderly Adults With Hypertension, by Sex
No. of CVD Events and CVD-Related Deaths Per 10,000 Populationa
Scenario/Sex

CHD

Stroke

CVD Death

Baseline scenario: no expansion, no. (95% CI)
Total

2,022 (1,914–2,130)

837 (769–905)

816 (763–869)

Male

1,366 (1,303–1,429)

424 (391–457)

474 (446–502)

648 (603–693)

421 (386–456)

342 (317–367)

2,011 (1,906–2,116)

831 (763–899)

806 (753–859)

11.1 (−0.55)

6.3 (−0.75)

9.5 (−1.16)

1,358 (1,297–1,419)

420 (385–455)

468 (440–496)

Female

Scenario 1: currently undecided states opting out of Medicaid expansion
Total, no. (95% CI)
Difference (% change)
Male, no. (95% CI)
Difference (% change)

8.3 (−0.61)

4.1 (−0.96)

5.8 (−1.23)

645 (596–694)

419 (379–459)

338 (303–373)

2.8 (−0.43)

2.3 (−0.54)

3.7 (−1.07)

1,992 (1,884–2,100)

826 (761–891)

794 (744–844)

29.9 (−1.48)

10.9 (−1.30)

22.2 (−2.73)

1,344 (1,281–1,407)

418 (386–450)

460 (434–486)

21.9 (−1.6)

6.3 (−1.49)

14.0 (−2.96)

640 (590–690)

416 (377–455)

334 (299–369)

7.9 (−1.21)

4.8 (−1.14)

8.2 (−2.41)

Female, no. (95% CI)
Difference (% change)
Scenario 2: all US population under insurance coverage
Total, no. (95% CI)
Difference (% change)
Male, no. (95% CI)
Difference (% change)
Female, no. (95% CI)
Difference (% change)

Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease.
a Values expressed as no. (95% CI), unless otherwise indicated. 95% CIs obtained from Monte Carlo simulations.
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Table 3. Estimated Effects of Health Insurance Expansion on Nonelderly Adults with Hypertension, By Race/Ethnicitya,b
CVD Events and CVD-Related Deaths Per 10,000 population
Scenario and Race/Ethnicity

CHD

Stroke

CVD death

Baseline scenario: no expansion, no. (95% CI)
White

1,310 (1,237–1,383)

534 (488–580)

528 (491–565)

Black

340 (321–359)

175 (162–188)

152 (143–161)

22.8 (21.6–24.0)

7.6 (6.9–8.3)

5.0 (4.5–5.5)

1,304 (1,231–1,377)

531 (485–577)

522 (487–557)

6.7 (−0.51)

2.7 (−0.5)

6.3 (−1.19)

336 (318–354)

173 (160–186)

148 (139–157)

Nonwhite Hispanic

Scenario 1: currently undecided states opting out of Medicaid expansion
White, no. (95% CI)
Difference (% change)
Black, no. (95% CI)
Difference (% change)
Nonwhite Hispanic, no. (95% CI)
Difference (% change)

3.5 (−1.04)

1.9 (−1.1)

3.2 (−2.14)

22.4 (21.1–23.6)

7.5 (6.8–8.2)

4.8 (4.4–5.2)

0.5 (−2.07)

0.1 (−1.06)

0.2 (−3.84)

1,295 (1,223–1,367)

529 (484–574)

517 (482–552)

15.4 (−1.17)

4.6 (−0.87)

11.3 (−2.15)

332 (314–350)

172 (159–185)

146 (137–155)

7.2 (−2.12)

3.5 (−1.97)

6.1 (−4)

21.6 (20.5–22.7)

7.4 (6.7–8.1)

4.5 (4.1–4.9)

1.3 (−5.63)

0.2 (−2.57)

0.5 (−9.79)

Scenario 2: all US population under insurance coverage
White, no. (95% CI)
Difference (% change)
Black, no. (95% CI)
Difference (% change)
Nonwhite Hispanic, no. (95% CI)
Difference (% change)

Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease.
a Values expressed as no. (95% CI), unless otherwise indicated. 95% CIs obtained from Monte Carlo simulations.
b Pre- and post-ACA insurance rates for race/ethnicity groups were adjusted according to the age distribution of insurance status reported by The Kaiser Commission on Medicaid and the Uninsured (12).
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Appendix.
Estimation of Model Input Parameters and Results of Sensitivity Analysis. This file is available for download as a Microsoft
Word document [DOCX – 32.8 KB].
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